Tuebingen

• NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll … Recruiting
  2025-522091-84-00 4 2026-05-29 Merkel Cell Carcinoma
• Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury Recruiting
  2025-523914-10-00 6 2026-04-30 Critical illness
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Statur … Recruiting
  2025-523079-44-00 5 2026-04-15 Turner Syndrome (TS)
• Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting
  2025-522583-32-00 5 2026-04-13 Cold-Induced Urticaria and Symptomatic Dermographism
• Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting
  2025-522403-17-00 5 2026-04-10 Nummular Dermatitis
• A phase I/IIa, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) … Recruiting
  2024-511266-36-00 7 2026-03-26 The clinical trial itself does not investigate a medical condition or
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Adjuvant radioligand therapy in neuroendocrine tumors Recruiting
  2024-518236-36-00 5 2026-03-12 Locoregionally restricted (stage III) small intestinal neuroendocrine
• Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults Recruiting
  2024-518273-34-02 3 2026-03-02 Malaria
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD) Recruiting
  2024-517413-33-00 4 2026-02-03 Idiopathic Parkinson's Disease
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantatio … Recruiting
  2025-521372-62-00 4 2026-01-29 Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute Myeloid Le
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal micr … Recruiting
  2024-519748-34-00 4 2026-01-23 Infections with multidrug-resistant Enterobacteriaceae
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place … Recruiting
  2024-519829-38-00 5 2026-01-09 Heart failure due to systemic left ventricular systolic dysfunction
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc … Recruiting
  2022-500676-59-00 4 2025-12-18 EBV-positive nasopharyngeal carcinoma
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 11 2025-12-18 Neovascular age-related macular degeneration
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan … Recruiting
  2025-521128-31-00 9 2025-12-18 Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting
  2024-517980-22-00 4 2025-12-10 Multiple Sclerosis (MS)

Showing 97–120 of 591 trials